Continuous therapy in HHV-8 negative Multicentric Castleman Disease and prolonged progression-free survival.
Castleman Disease
Continuous therapy
HHV-8 negative Multicentric Castleman Disease
Journal
Journal of hematology & oncology
ISSN: 1756-8722
Titre abrégé: J Hematol Oncol
Pays: England
ID NLM: 101468937
Informations de publication
Date de publication:
06 Aug 2024
06 Aug 2024
Historique:
received:
28
05
2024
accepted:
01
08
2024
medline:
7
8
2024
pubmed:
7
8
2024
entrez:
6
8
2024
Statut:
epublish
Résumé
The optimal treatment endpoints and duration of continuous therapy for multicentric Castleman disease (MCD) remain controversial. We retrospectively analyzed data from 123 patients with Human Herpesvirus (HHV)-8 negative MCD. We demonstrated that continuous therapy significantly enhanced progression-free survival (PFS) in patients who achieved an optimal response after initial treatment. These findings underscore the critical role of continuous therapy in HHV-8 negative MCD. Further studies with larger cohorts are required to validate these findings.
Identifiants
pubmed: 39107807
doi: 10.1186/s13045-024-01588-9
pii: 10.1186/s13045-024-01588-9
doi:
Types de publication
Letter
Langues
eng
Sous-ensembles de citation
IM
Pagination
60Subventions
Organisme : National Natural Science Foundation of China
ID : 82100241
Organisme : Natural Science Foundation of Zhejiang Province
ID : LZ23H080002
Informations de copyright
© 2024. The Author(s).
Références
Carbone A, Borok M, Damania B, et al. Castleman disease. Nat Rev Dis Primers. 2021;7:84.
doi: 10.1038/s41572-021-00317-7
pubmed: 34824298
pmcid: 9584164
van Rhee F, Oksenhendler E, Srkalovic G, et al. International evidence-based consensus diagnostic and treatment guidelines for unicentric Castleman disease. Blood Adv. 2020;4:6039–50.
doi: 10.1182/bloodadvances.2020003334
pubmed: 33284946
pmcid: 7724917
Dispenzieri A, Fajgenbaum DC. Overview of Castleman disease. Blood. 2020;135:1353–64.
doi: 10.1182/blood.2019000931
pubmed: 32106302
Zhang L, Dong Y, Peng H, et al. A National, Multicenter, Retrospective Study of Castleman Disease Implementing Cdcn Criteria: ‘severe Imcd’ is indeed severe. Blood. 2022;140:3609–11.
doi: 10.1182/blood-2022-158675
van Rhee F, Casper C, Voorhees PM, et al. A phase 2, open-label, multicenter study of the long-term safety of siltuximab (an anti-interleukin-6 monoclonal antibody) in patients with multicentric Castleman disease. Oncotarget. 2015;6:30408–19.
doi: 10.18632/oncotarget.4655
pubmed: 26327301
pmcid: 4745809
Yu L, Tu M, Cortes J, et al. Clinical and pathological characteristics of HIV- and HHV-8-negative Castleman disease. Blood. 2017;129:1658–68.
doi: 10.1182/blood-2016-11-748855
pubmed: 28100459
pmcid: 5364343
Tonialini L, Bonfichi M, Ferrero S, et al. Siltuximab in relapsed/refractory multicentric Castleman disease: experience of the Italian NPP program. Hematol Oncol. 2018;36:689–92.
doi: 10.1002/hon.2532
pubmed: 30074630
Ostrowska B, Szymczyk A, Olszewska-Szopa M, et al. Efficacy of siltuximab in the treatment of idiopathic multicentric castleman disease, the first Polish, real-world experience with long-term observation. Leuk Lymphoma. 2021;62:3031–4.
doi: 10.1080/10428194.2021.1941926
pubmed: 34159888
Min G-J, Jeon Y-W, Park S-S, et al. The clinical, laboratory, and radiologic improvement due to siltuximab treatment in idiopathic multicentric Castleman’s disease. Korean J Intern Med. 2021;36:424–32.
doi: 10.3904/kjim.2019.330
pubmed: 32088937
van Rhee F, Voorhees P, Dispenzieri A, et al. International, evidence-based consensus treatment guidelines for idiopathic multicentric Castleman disease. Blood. 2018;132:2115–24.
doi: 10.1182/blood-2018-07-862334
pubmed: 30181172
pmcid: 6238190